Epizyme to Participate in Three Upcoming Conferences

Cambridge, MA, February 10, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held during February.

• Robert Gould, Ph.D., President and CEO, will present at the Leerink Swann 2012 Global Healthcare Conference being held at the Waldorf Astoria Hotel in New York City on February 15, 2012 at 2:00 PM.
• Dr. Gould will also present at the Citi 2012 Global Healthcare Conference, which is being held February 27-29, 2012, also at the Waldorf Astoria Hotel in New York City. Dr. Gould will present on Tuesday, February 28^th, at 4:00 PM.
• Jason P. Rhodes, Executive Vice President and CBO, will participate in the Featured Joint Presentation, “Investments, Partnerships & Acquisitions: Trends & Recent Deals,” at 8:00 AM, as well as a panel discussion at 10:55 AM on Monday, February 27^th at the Oncology Partnering & Deal Making Conference being held at the Red Rock Casino Resort and Spa in Las Vegas, February 27-28, 2012. The conference is part of the Targets and Strategies in Drug Discovery Summit, hosted by the Global Technology Community (GTC).

Epizyme’s therapeutics discovery programs are focused on histone methyltransferases (HMTs), a class of epigenetic enzymes that play an important role in regulating pathways of genes that are strongly associated with the underlying causes of many human diseases, including cancer. Epizyme announced a program-based partnership with Eisai for the epigenetic enzyme EZH2 in March 2011 and a multi-target drug discovery alliance with GlaxoSmithKline in January 2011 and also receives funding support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS).

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com

Media Contacts

Kari Watson or Jennifer Conrad

MacDougall Biomedical Communications